Charles Duncan
Stock Analyst at Cantor Fitzgerald
(3.47)
# 928
Out of 5,090 analysts
226
Total ratings
46.01%
Success rate
20.83%
Average return
Main Sectors:
Stocks Rated by Charles Duncan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CMPS COMPASS Pathways | Reiterates: Overweight | n/a | $5.82 | - | 6 | Mar 28, 2025 | |
| ACAD ACADIA Pharmaceuticals | Reiterates: Overweight | $28 | $27.44 | +2.04% | 21 | Feb 27, 2025 | |
| JAZZ Jazz Pharmaceuticals | Downgrades: Neutral | $140 → $150 | $169.70 | -11.61% | 6 | Feb 26, 2025 | |
| AXSM Axsome Therapeutics | Reiterates: Overweight | $153 | $149.22 | +2.53% | 22 | Feb 19, 2025 | |
| GHRS GH Research | Initiates: Overweight | $14 | $14.89 | -5.98% | 1 | Feb 13, 2025 | |
| DRUG Bright Minds Biosciences | Initiates: Overweight | n/a | $80.50 | - | 1 | Jan 10, 2025 | |
| BHVN Biohaven | Reiterates: Overweight | n/a | $9.55 | - | 17 | Dec 17, 2024 | |
| STOK Stoke Therapeutics | Reiterates: Overweight | n/a | $30.87 | - | 7 | Dec 10, 2024 | |
| HRMY Harmony Biosciences Holdings | Maintains: Overweight | $51 → $58 | $39.83 | +45.62% | 8 | Oct 30, 2024 | |
| ALKS Alkermes | Maintains: Overweight | $48 → $43 | $29.52 | +45.66% | 5 | Oct 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $65.67 | - | 7 | Oct 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $11.07 | - | 15 | Sep 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $155 | $155.51 | -0.33% | 9 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $16.43 | - | 3 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $35 | $19.96 | +75.35% | 6 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $11 → $13 | $5.39 | +141.19% | 5 | Aug 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $5.99 | - | 6 | Jul 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.73 | - | 2 | Jul 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $12.35 | - | 3 | Jun 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $4.32 | - | 3 | Jun 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $34 | $23.53 | +44.50% | 9 | Mar 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $52 → $50 | $46.67 | +7.14% | 3 | Oct 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $5 | $5.77 | -13.34% | 1 | Sep 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $4 | $0.36 | +1,008.03% | 4 | Sep 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $4 | $1.03 | +288.35% | 4 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $58 | $45.01 | +28.86% | 3 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $1,100 | $1.58 | +69,520.25% | 4 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $80 | $5.77 | +1,286.48% | 5 | Aug 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $3 | $1.05 | +185.71% | 2 | Aug 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $16 → $11 | $4.40 | +150.00% | 2 | Dec 6, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $9 → $12 | $7.55 | +58.94% | 2 | Nov 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $146 → $168 | $6.91 | +2,331.26% | 6 | Jun 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $20 | $2.69 | +643.49% | 1 | Feb 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $200 | $27.35 | +631.26% | 3 | Feb 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $8 → $4 | $1.67 | +139.52% | 3 | Apr 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $24 | $3.19 | +652.35% | 1 | Oct 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $372 → $144 | $2.07 | +6,856.52% | 6 | Sep 28, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $3 → $4 | $1.31 | +205.34% | 2 | Jun 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $35 → $39 | $63.33 | -38.42% | 4 | May 4, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $14 → $15 | $86.11 | -82.58% | 4 | Feb 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | n/a | $0.50 | - | 3 | Nov 15, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $180 | $5.24 | +3,335.11% | 1 | Oct 9, 2017 |
COMPASS Pathways
Mar 28, 2025
Reiterates: Overweight
Price Target: n/a
Current: $5.82
Upside: -
ACADIA Pharmaceuticals
Feb 27, 2025
Reiterates: Overweight
Price Target: $28
Current: $27.44
Upside: +2.04%
Jazz Pharmaceuticals
Feb 26, 2025
Downgrades: Neutral
Price Target: $140 → $150
Current: $169.70
Upside: -11.61%
Axsome Therapeutics
Feb 19, 2025
Reiterates: Overweight
Price Target: $153
Current: $149.22
Upside: +2.53%
GH Research
Feb 13, 2025
Initiates: Overweight
Price Target: $14
Current: $14.89
Upside: -5.98%
Bright Minds Biosciences
Jan 10, 2025
Initiates: Overweight
Price Target: n/a
Current: $80.50
Upside: -
Biohaven
Dec 17, 2024
Reiterates: Overweight
Price Target: n/a
Current: $9.55
Upside: -
Stoke Therapeutics
Dec 10, 2024
Reiterates: Overweight
Price Target: n/a
Current: $30.87
Upside: -
Harmony Biosciences Holdings
Oct 30, 2024
Maintains: Overweight
Price Target: $51 → $58
Current: $39.83
Upside: +45.62%
Alkermes
Oct 25, 2024
Maintains: Overweight
Price Target: $48 → $43
Current: $29.52
Upside: +45.66%
Oct 18, 2024
Reiterates: Overweight
Price Target: n/a
Current: $65.67
Upside: -
Sep 30, 2024
Reiterates: Overweight
Price Target: n/a
Current: $11.07
Upside: -
Sep 16, 2024
Reiterates: Overweight
Price Target: $155
Current: $155.51
Upside: -0.33%
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $16.43
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: $35
Current: $19.96
Upside: +75.35%
Aug 1, 2024
Maintains: Overweight
Price Target: $11 → $13
Current: $5.39
Upside: +141.19%
Jul 31, 2024
Reiterates: Overweight
Price Target: n/a
Current: $5.99
Upside: -
Jul 30, 2024
Downgrades: Neutral
Price Target: n/a
Current: $1.73
Upside: -
Jun 21, 2024
Reiterates: Overweight
Price Target: n/a
Current: $12.35
Upside: -
Jun 21, 2024
Reiterates: Overweight
Price Target: n/a
Current: $4.32
Upside: -
Mar 22, 2024
Reiterates: Overweight
Price Target: $34
Current: $23.53
Upside: +44.50%
Oct 24, 2023
Assumes: Overweight
Price Target: $52 → $50
Current: $46.67
Upside: +7.14%
Sep 22, 2023
Initiates: Overweight
Price Target: $5
Current: $5.77
Upside: -13.34%
Sep 7, 2023
Reiterates: Overweight
Price Target: $4
Current: $0.36
Upside: +1,008.03%
Aug 22, 2023
Reiterates: Overweight
Price Target: $4
Current: $1.03
Upside: +288.35%
Aug 22, 2023
Reiterates: Overweight
Price Target: $58
Current: $45.01
Upside: +28.86%
Aug 22, 2023
Reiterates: Overweight
Price Target: $1,100
Current: $1.58
Upside: +69,520.25%
Aug 16, 2023
Reiterates: Overweight
Price Target: $80
Current: $5.77
Upside: +1,286.48%
Aug 14, 2023
Reiterates: Overweight
Price Target: $3
Current: $1.05
Upside: +185.71%
Dec 6, 2022
Downgrades: Neutral
Price Target: $16 → $11
Current: $4.40
Upside: +150.00%
Nov 22, 2022
Upgrades: Overweight
Price Target: $9 → $12
Current: $7.55
Upside: +58.94%
Jun 8, 2022
Maintains: Overweight
Price Target: $146 → $168
Current: $6.91
Upside: +2,331.26%
Feb 18, 2022
Initiates: Overweight
Price Target: $20
Current: $2.69
Upside: +643.49%
Feb 18, 2022
Initiates: Overweight
Price Target: $200
Current: $27.35
Upside: +631.26%
Apr 20, 2021
Downgrades: Neutral
Price Target: $8 → $4
Current: $1.67
Upside: +139.52%
Oct 23, 2020
Initiates: Overweight
Price Target: $24
Current: $3.19
Upside: +652.35%
Sep 28, 2020
Downgrades: Neutral
Price Target: $372 → $144
Current: $2.07
Upside: +6,856.52%
Jun 1, 2020
Maintains: Overweight
Price Target: $3 → $4
Current: $1.31
Upside: +205.34%
May 4, 2020
Reiterates: Overweight
Price Target: $35 → $39
Current: $63.33
Upside: -38.42%
Feb 21, 2020
Reiterates: Neutral
Price Target: $14 → $15
Current: $86.11
Upside: -82.58%
Nov 15, 2017
Upgrades: Overweight
Price Target: n/a
Current: $0.50
Upside: -
Oct 9, 2017
Initiates: Overweight
Price Target: $180
Current: $5.24
Upside: +3,335.11%